Fidelity Investments
BDTX icon

Fidelity Investments’s Black Diamond Therapeutics BDTX Stock Holding History

Fidelity Investments’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
643,668
+19,841
+3% +$48.5K ﹤0.01% 2936
2026
Q1 		$1.33M Buy
623,827
+82,673
+15% +$197K ﹤0.01% 2775
2025
Q4 		$1.32M Buy
541,154
+87,596
+19% +$310K ﹤0.01% 2748
2025
Q3 		$1.72M Buy
453,558
+39,672
+10% +$116K ﹤0.01% 2599
2025
Q2 		$1.03M Buy
413,886
+75,217
+22% +$145K ﹤0.01% 2712
2025
Q1 		$525K Buy
338,669
+142,542
+73% +$299K ﹤0.01% 2882
2024
Q4 		$420K Buy
196,127
+17,059
+10% +$48.9K ﹤0.01% 2996
2024
Q3 		$779K Buy
+179,068
New +$974K ﹤0.01% 2683
2024
Q1 		– Sell
-2
Closed -$6 – 5369
2023
Q4 		$6 Hold
2
– – ﹤0.01% 5359
2023
Q3 		$6 Sell
2
-16
-89% -$59 ﹤0.01% 5211
2023
Q2 		$92 Sell
18
-66
-79% -$135 ﹤0.01% 4969
2023
Q1 		$158 Buy
84
+75
+833% +$172 ﹤0.01% 4869
2022
Q4 		$16 Sell
9
-281
-97% -$506 ﹤0.01% 5164
2022
Q3 		$0 Buy
290
+254
+706% +$783 ﹤0.01% 4854
2022
Q2 		$0 Sell
36
-14,622
-100% -$34K ﹤0.01% 4916
2022
Q1 		$41K Buy
14,658
+14,649
+162,767% +$53.5K ﹤0.01% 3741
2021
Q4 		$0 Hold
9
– – ﹤0.01% 4333
2021
Q3 		$0 Sell
9
-360,420
-100% -$3.56M ﹤0.01% 4339
2021
Q2 		$4.39M Sell
360,429
-1,730,859
-83% -$34.2M ﹤0.01% 2364
2021
Q1 		$50.7M Buy
2,091,288
+429,631
+26% +$11.6M ﹤0.01% 1396
2020
Q4 		$53.3M Buy
1,661,657
+264,005
+19% +$8.67M ﹤0.01% 1291
2020
Q3 		$42.3M Sell
1,397,652
-27,283
-2% -$830K ﹤0.01% 1261
2020
Q2 		$60.1M Sell
1,424,935
-163,075
-10% -$6M 0.01% 1088
2020
Q1 		$39.6M Buy
+1,588,010
New +$48.3M 0.01% 1120

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Fidelity Investments's BDTX Position: Q2 2026 in Review

Fidelity Investments increased its Black Diamond Therapeutics (BDTX) stake by 3.2% in Q2 2026, buying an estimated $48.5K and bringing the position to 643,668 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2936.

Fidelity Investments first reported a position in BDTX in Q1 2020 and has held it in 24 quarters since. The position peaked at $60.1M in Q2 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Fidelity Investments held 643,668 shares of Black Diamond Therapeutics worth $1.19M as of Q2 2026.
  • Fidelity Investments bought 19,841 Black Diamond Therapeutics shares in Q2 2026, an estimated $48.5K.
  • Black Diamond Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2936 holding.
  • Fidelity Investments first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 24 quarters since.
  • Fidelity Investments's Black Diamond Therapeutics position peaked at $60.1M in Q2 2020.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.